entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 19:58:24 - browse：99855

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： White House drug czar issues call for 'recovery

hotspot

WSS

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Study suggests Covid rebound is far more common with Paxlovid than without

Telehealth startups are trying to fill the menopause care vacuum

Cancer diagnosis changes perspective doctor, former hospital CEO

Extensive review finds private equity owners jack up cost of care

focus

entertainment

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Psychedelics group wrestles with new pharma identity

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Heart attack and stroke risk calculators need revising

How a Boston hospital is priming medical residents to use GPT

Heart attack and stroke risk calculators need revising

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

How to save PrEP access — and even expand it

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Wikipedia

Publishing genetic code of viruses could cause disaster

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Caribou posts encouraging results on off

Healthy food access boosts outcomes in two studies

A letter from the executive editor: STAT UnitedHealth investigation

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

entertainment

hotspot

hotspot

focus